Achillion Pharmaceuticals trades as part of the biotechnology industry and is in the healthcare sector. The company CEO is Joseph Truitt. Achillion Pharmaceuticals Inc is a biotechnology company. It is engaged in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders.
Previous Intraday Performance:
The ACHN shares had a previous change of 1.07% which opened at 2.82 and closed at 2.84. It moved to an intraday high of 2.90 and a low of 2.79.
SeekingAlpha: ACHN and CRAY among premarket gainers
Historical Performance:
Over the last five trading days, ACHN shares returned -3.07% and in the past 30 trading days it returned -11.80%. Over three months, it changed 15.92%. In one year it has changed -22.40% and within that year its 52 week high was 3.98 and its 52 week low was 1.29. ACHN stock is 120.16% above its 52 week low.
Our calculations result in a 200 day moving average of 2.81 and a 50 day moving average of 3.02. Right now, ACHN stock is trading 1.09% above its 200 day moving average and may be a good opportunity to buy.
SeekingAlpha: Achillion’s ACH-4471 shows encouraging action in PNH study; shares ahead 7% premarket
Liquidity:
The company has a market cap of $394.0m with 138.7m shares outstanding and a float of 138.4m shares. Trading volume was 1,975,469 shares and has experienced an average volume of 1,285,805 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Achillion Pharmaceuticals was -0.51 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.13.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr 2019 | -0.14 |
|---|---|---|
| 4th | Qtr 2018 | -0.12 |
| 3rd | Qtr 2018 | -0.12 |
| 2nd | Qtr 2018 | -0.12 |
| 1st | Qtr 2018 | -0.15 |
The long-term trend of the EPS is an important number as it indicates the present value of Achillion Pharmaceuticals.
Indicators Also to Watch:
Based on the latest filings, there is 95.30% of institutional ownership.
The beta was calculated to be 2.39.
SeekingAlpha: Achillion’s ACH-4471 shows encouraging action in PNH study; shares ahead 7% premarket
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -25.96%, return on assets is -24.96% and price-to-book is 1.58.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: Achillion Pharmaceuticals, ACHN, Biotechnology, Healthcare
